Chronic Urticaria: An Overview of Treatment and Recent Patents.
CONCLUSION: CU is idiopathic in majority of cases. On average, the duration of CU is around two to five years. Treatment is primarily symptomatic. Second generation antihistamines are first line. Omaluzimab has been a remarkable advance in the management of CU and improves quality of life beyond symptom control.
PMID: 30924425 [PubMed - as supplied by publisher]
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research
More News: Allergy | Allergy & Immunology | Anxiety | Clinical Trials | Corticosteroid Therapy | Depression | Education | Epidemiology | Hives | Restasis | Skin | Universities & Medical Training | Xolair